- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Marietta, Georgia • Lexington, Kentucky • Glen Burnie, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Anne Fung MD
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Macular Degeneration
- Interventions
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Abilene, Texas
- Conditions
- Geographic Atrophy
- Interventions
- OCU410
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
- Conditions
- Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
- Interventions
- i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
- Device
- Lead sponsor
- i-Lumen Scientific, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
- Conditions
- Macular Degeneration
- Interventions
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Geographic Atrophy of the Macula, Macular Degeneration
- Interventions
- AVD-104, Avacincaptad
- Drug
- Lead sponsor
- Aviceda Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 56
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Interventions
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Drug · Procedure
- Lead sponsor
- Harrow Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
- Interventions
- Anterior Chamber (AC) Tap
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
- Drug · Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Glendale, California • Loma Linda, California • Oakland, California + 49 more
- Conditions
- Retinal Vein Occlusion, Macular Edema, Cystoid, Macular Edema
- Interventions
- Triamcinolone Acetonide
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 9
- States / cities
- Boynton Beach, Florida • Fort Meyers, Florida • Miami, Florida + 6 more
- Conditions
- Stargardt Disease, Macular Atrophy
- Interventions
- Emixustat
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Avacincaptad Pegol, Lucentis
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- GT005
- Drug
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 331,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
- Conditions
- Macular Edema, Uveitis
- Interventions
- Ozurdex Intravitreal Injection (0.7 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Fluocinolone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Pensacola, Florida • Chesterfield, Missouri • Charlotte, North Carolina + 8 more